Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.64 |
| ▸ | MEN1 | O00255 | 4/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | NPC1 | O15118 | 7/20 | 0.52 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.44 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212382 | 0.85 | RAB9A (0.68) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL28091339 | 0.85 | RAB9A (0.68) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL4134670 | 0.84 | NOTUM (0.54) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| Hydrochloric Acid SCHEMBL8880218 | 0.84 | RAB9A (0.66) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL368446 | 0.83 | CYP2C9 (0.54) | RAB9ASMN1; SMN2ALDH1A1NPC1CYP1A2 | |
| SCHEMBL17883944 | 0.83 | MEN1 (0.56) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL8878902 | 0.83 | MAPT (0.49) | RAB9ASMN1; SMN2MEN1KMT2ANPC1 | |
| SCHEMBL4339549 | 0.82 | RAB9A (0.46) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL4805 | 0.82 | RAB9A (0.69) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 | |
| SCHEMBL3985673 | 0.82 | RAB9A (0.64) | RAB9ASMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2024-05-02 | — | — | US | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| EP-3237411-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | PROTEOSTASIS THERAPEUTICS INC (US) | 2022-06-09 | — | — | US | disclosed |
| CN-107207487-B | Compounds, compositions and methods for increasing CFTR activity | 蛋白质平衡治疗股份有限公司 | 2021-12-28 | — | — | CN | disclosed |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | PROTEOSTASIS THERAPEUTICS, INC. (US) | 2021-08-10 | — | — | US | disclosed |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | PROTEOSTASIS THERAPEUTICS, INC. | 2020-11-19 | — | — | US | disclosed |
| WO-2004032848-A2 | PGD2 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY DISEASES | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2004-04-22 | — | — | WO | disclosed |
| CN-1040105-C | Aminoketone derivatives and use thereof | MITZUI TOATSU CHEMICALS INC (JP) | 1998-10-07 | — | — | CN | disclosed |
| US-5602160-A | MUSCLE RELAXANT | MITSUI TOATSU CHEMICALS INCORPORATED (JP) | 1997-02-11 | — | — | US | disclosed |
| US-5498619-A | MUSCLE RELAXANTS, POLLAKIUREA CURING AGENTS AND MUSCLE SPASMS | MITSUI TOATSU CHEMICALS, INCORPORATED (JP) | 1996-03-12 | — | — | US | disclosed |
| EP-0414391-B1 | Aminoketone derivatives and use thereof | MITSUI TOATSU CHEMICALS (JP) | 1995-03-15 | — | — | EP | disclosed |
| US-5338857-A | Muscle relaxant | MITSUI TOATSU CHEMICALS INCORPORATED (JP) | 1994-08-16 | — | — | US | disclosed |
| EP-0378111-B1 | Isoxazole derivatives having anti-serotonin activity, their preparation process and compositions containing them | ZAMBON SPA (IT) | 1994-06-01 | — | — | EP | disclosed |
| CN-1049660-A | Aminoketone derivative and application thereof | MITZUI TOATSU CHEMICALS INC (JP) | 1991-03-06 | — | — | CN | disclosed |
| EP-0414391-A2 | Aminoketone derivatives and use thereof | MITSUI TOATSU CHEMICALS, Inc. (JP) | 1991-02-27 | — | — | EP | disclosed |
| US-4988691-A | Analgesics, cardiovascular disorders, nervous system disorders | ZAMBON GROUP S.P.A. (IT) | 1991-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240139158-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | RAB9A 1690/4885SMN1; SMN2 1913/4885MEN1 3829/4885 |
| US-20200360348-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF INCREASING CFTR ACTIVITY | CFTR, ABCB4, SCNN1B | RAB9A 840/4885SMN1; SMN2 3701/4885MEN1 4523/4885 |
| US-11083709-B2 | Compounds, compositions, and methods of increasing CFTR activity | CFTR, ABCB4, SCNN1B | RAB9A 840/4885SMN1; SMN2 3701/4885MEN1 4523/4885 |
| US-20220175735-A1 | METHODS OF TREATING PULMONARY DISEASES AND DISORDERS | SMPD1, ELANE, SMPD2 | RAB9A 1690/4885SMN1; SMN2 1913/4885MEN1 3829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.